Compare · MRNA vs ZURA
MRNA vs ZURA
Side-by-side comparison of Moderna Inc. (MRNA) and Zura Bio Limited (ZURA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and ZURA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $26.76B, about 55.7x ZURA ($480.7M).
- Over the past year, MRNA is up 113.5% and ZURA is up 296.9% - ZURA leads by 183.4 points.
- ZURA has been more active in the news (11 items in the past 4 weeks vs 9 for MRNA).
- MRNA has more recent analyst coverage (25 ratings vs 10 for ZURA).
- Company
- Moderna Inc.
- Zura Bio Limited
- Price
- $67.43+0.66%
- $5.08-1.65%
- Market cap
- $26.76B
- $480.7M
- 1M return
- +35.80%
- +41.90%
- 1Y return
- +113.52%
- +296.88%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 11
- Recent ratings
- 25
- 10
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- SEC Form 4 filed by Director Mcdonnell Michael R.
- SEC Form 3 filed by new insider Mcdonnell Michael R.
- Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
- Moderna Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Moderna Appoints Michael McDonnell to Board of Directors
- SEC Form 4 filed by Chief Commercial Officer Banque Soria Ester
- Chief Financial Officer Mock James M converted options into 1,452 shares and covered exercise/tax liability with 703 shares, increasing direct ownership by 1% to 66,436 units (SEC Form 4) to satisfy withholding tax
- SEC Form 3 filed by new insider Banque Soria Ester
- Moderna Science Day Highlights Expanding Potential of mRNA Platform
- Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
Latest ZURA
- William Blair initiated coverage on Zura Bio Limited
- Zura Bio Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
- New insider Mathew Marlyn Teresa claimed ownership of 129,182 units of Class A Ordinary Shares (SEC Form 3)
- SEC Form 4 filed by Director Jarrett Jennifer
- SEC Form 4 filed by Director Thiara Parvinder
- SEC Form 4 filed by Director Schoch Steven J
- SEC Form 4 filed by Director Nirula Ajay
- SEC Form 4 filed by Director Eisner Mark
- SEC Form 4 filed by Director Munshi Amit